Literature DB >> 19408046

Risk factors for massive blood transfusion in cytoreductive surgery: a multivariate analysis of 243 procedures.

Akshat Saxena1, Tristan D Yan, Terence C Chua, Sal Fransi, Khaled Almohaimeed, Sulman Ahmed, David L Morris.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) has demonstrated improved survival in selected patients with peritoneal carcinomatosis (PC). This treatment modality is associated with high blood loss and often requires massive allogenic red blood cell transfusion (MABT). Our study is the first of its kind to evaluate the risk factors for intraoperative MABT in peritonectomy procedures.
METHODS: Two hundred and forty-three consecutive CRS and PIC procedures were evaluated. The associations between 17 preoperative and intraoperative risk factors and intraoperative MABT (>or=6 units) were assessed by univariate and multivariate analysis.
RESULTS: One hundred and eighty-six (77%) procedures required intraoperative transfusion of packed red blood cells. Ninety-one procedures required MABT (37%). Multivariate analysis showed six significant risk factors for intraoperative MABT: operative length > 9 h (p < 0.001), preoperative hemoglobin < 125 g/l (p < 0.001), operation date prior to 2004 (p = 0.002), peritoneal cancer index >or= 16 (p = 0.006), preoperative international normalized ratio (INR) >or= 1.2 (p = 0.008), and number of peritonectomy procedures >or= 4 (p = 0.021). Statistical analysis also revealed that MABT was associated with increased intensive care unit (ICU) (p < 0.001), high-dependency unit (HDU) (p = 0.020), and total hospital stay (p < 0.001) and with severe morbidity (p < 0.001).
CONCLUSIONS: Patients with preoperative anemia, impaired coagulation profile or extensive tumor burden are at high risk of MABT. Appropriate blood conservation strategies should be adopted in these patients on the basis of their risk factors.

Entities:  

Mesh:

Year:  2009        PMID: 19408046     DOI: 10.1245/s10434-009-0484-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Effectiveness of early and aggressive administration of fresh frozen plasma to reduce massive blood transfusion during cytoreductive surgery.

Authors:  Akshat Saxena; Terence C Chua; Salwan Fransi; Winston Liauw; David L Morris
Journal:  J Gastrointest Oncol       Date:  2013-03

2.  Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis.

Authors:  Boateng Kubi; Richard Nudotor; Nadege Fackche; Wasay Nizam; Jordan M Cloyd; Travis E Grotz; Keith F Fournier; Sean P Dineen; Benjamin D Powers; Jula Veerapong; Joel M Baumgartner; Callisia N Clarke; Sameer H Patel; Laura A Lambert; Daniel E Abbott; Kara A Vande Walle; Mustafa Raoof; Byrne Lee; Shishir K Maithel; Charles A Staley; Fabian M Johnston; Jonathan B Greer
Journal:  Ann Surg Oncol       Date:  2021-01-28       Impact factor: 5.344

Review 3.  Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.

Authors:  Megan M Harper; Joseph Kim; Prakash K Pandalai
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

4.  Allogenic Blood Transfusion Is an Independent Predictor of Poorer Peri-operative Outcomes and Reduced Long-Term Survival after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a Review of 936 Cases.

Authors:  Akshat Saxena; Sarah J Valle; Winston Liauw; David L Morris
Journal:  J Gastrointest Surg       Date:  2017-05-30       Impact factor: 3.452

5.  A critical evaluation of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis.

Authors:  Akshat Saxena; Tristan D Yan; David L Morris
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

6.  Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy.

Authors:  Hamed Elgendy; Hanaa Nafady-Hego; Hanan M Abd Elmoneim; Talha Youssef; Abdulaziz Alzahrani
Journal:  Indian J Anaesth       Date:  2019-10-10

7.  Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC).

Authors:  Sohan Lal Solanki; Sudipta Mukherjee; Vandana Agarwal; Raghu S Thota; Kalpana Balakrishnan; Shagun Bhatia Shah; Neha Desai; Rakesh Garg; Reshma P Ambulkar; Nitin Madhukar Bhorkar; Viplab Patro; Snita Sinukumar; Meenakshi V Venketeswaran; Malini P Joshi; Rajesh Holalu Chikkalingegowda; Vijaya Gottumukkala; Pascal Owusu-Agyemang; Avanish P Saklani; Sanket Sharad Mehta; Ramakrishnan Ayloor Seshadri; John C Bell; Sushma Bhatnagar; Jigeeshu V Divatia
Journal:  Indian J Anaesth       Date:  2019-12-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.